Prostate cancer is the most commonly diagnosed non-cutaneous neoplasm among
American males and is the second leading cause of cancer-related death. Prostate specific …

Purpose A long natural history and a predominant osseous pattern of metastatic spread are
impediments to the adoption of precision medicine in patients with prostate cancer. To …

Abstract Background Prostate cancer (PrCa) genomic heterogeneity causes resistance to
therapies such as androgen deprivation. Such heterogeneity can be deciphered in the …

Background The goal of our study was to investigate the molecular underpinnings
associated with the relatively aggressive clinical behavior of prostate cancer (PCa) in African …

Androgen deprivation is the mainstay of therapy for progressive prostate cancer. Despite
initial and dramatic tumor inhibition, most men eventually fail therapy and die of metastatic …

PURPOSE Comprehensive genomic profiling (CGP) is increasingly used for routine clinical
management of prostate cancer. To inform targeted treatment strategies, 3,476 clinically …

From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …

Prostate cancer is clinically heterogeneous, ranging from indolent to lethal disease.
Expression profiling previously defined three subtypes of prostate cancer, one (subtype-1) …

The remarkable variation in prostate cancer clinical behavior represents an opportunity to
identify and understand molecular features that can be used to stratify patients into clinical …

Background Global disparities in prostate cancer (PCa) incidence highlight the urgent need
to identify genomic abnormalities in prostate tumors in different ethnic populations including …